Arena Pharmaceuticals Secures Belviq Deal With CVS Caremark

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Source: Mauth Studios / Flickr

Arena Pharmaceuticals (NASDAQ:ARNA) and Eisai Inc. announced Monday that their weight loss drug, Belviq, will be available to more people thanks to a new partnership with CVS Caremark (NYSE:CVS), a pharmacy benefits manager.

Pharmacy benefits managers like Caremark act as a kind of intermediary within the health care system; PBMs are third-party administrators of prescription drug programs and are primarily responsible for processing and paying for prescription drug claims.

Employers and health plans that use CVS Caremark as a PBM have agreed to broaden the coverage of Belviq. In addition, the health insurer Aetna, which has been evaluating Belviq along with a competing drug made by Vivus, called Qsymia, announced it will now offer Belviq as a preferred brand to eligible patients through its pilot program to self-insured plan sponsors across the country.

An Arena Pharmaceuticals press release stated that as a result of the agreement with CVS Caremark, more than half of Americans with insurance should now have access to Belviq.

More Articles About:

To contact the reporter on this story: To contact the editor responsible for this story:

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business